MA38503A1 - Anti-il-33 antibodies and their uses - Google Patents

Anti-il-33 antibodies and their uses

Info

Publication number
MA38503A1
MA38503A1 MA38503A MA38503A MA38503A1 MA 38503 A1 MA38503 A1 MA 38503A1 MA 38503 A MA38503 A MA 38503A MA 38503 A MA38503 A MA 38503A MA 38503 A1 MA38503 A1 MA 38503A1
Authority
MA
Morocco
Prior art keywords
antibodies
attenuate
bind
interaction
inhibit
Prior art date
Application number
MA38503A
Other languages
French (fr)
Inventor
Andrew J Murphy
Nicholas J Papadopoulos
Jamie M Orengo
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2014/023930 external-priority patent/WO2014164959A2/en
Publication of MA38503A1 publication Critical patent/MA38503A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des anticorps qui se lient à l'interleukine-33 (il-33) et des procédés pour les utiliser. L'invention concerne des anticorps qui inhibent ou atténuent la signalisation médiée par l'il-33. Les anticorps selon l'invention peuvent servir à bloquer l'interaction il-33/st2. Rn variante, certains anticorps selon l'invention inhibent ou atténuent la signalisation médiée par l'il-33 sans bloquer l'interaction il-33/st2. Dans certains modes de réalisation, les anticorps selon l'invention sont des anticorps entièrement humains qui se lient à l'il-33 humain à une affinité élevée. Les anticorps selon l'invention sont utiles pour traiter les maladies et les troubles associés à la signalisation il-33 et/ou à l'expression cellulaire d'il-33, comme les maladies inflammatoires ou les maladies allergiques.This invention relates to antibodies that bind to interleukin-33 (IL-33) and methods for their use. The present invention provides antibodies that inhibit or attenuate il-33 mediated signaling. The antibodies according to the invention can be used to block the il-33 / st2 interaction. Alternatively, certain antibodies according to the invention inhibit or attenuate IL-33 mediated signaling without blocking the IL-33 / ST2 interaction. In some embodiments, the antibodies of the invention are all-human antibodies that bind to human at high affinity. The antibodies of the invention are useful for treating diseases and disorders associated with il-33 signaling and / or il-33 cell expression, such as inflammatory diseases or allergic diseases.

MA38503A 2013-03-13 2014-03-12 Anti-il-33 antibodies and their uses MA38503A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778687P 2013-03-13 2013-03-13
PCT/US2014/023930 WO2014164959A2 (en) 2013-03-13 2014-03-12 Anti-il-33 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MA38503A1 true MA38503A1 (en) 2017-07-31

Family

ID=56119034

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38503A MA38503A1 (en) 2013-03-13 2014-03-12 Anti-il-33 antibodies and their uses

Country Status (2)

Country Link
AR (1) AR095235A1 (en)
MA (1) MA38503A1 (en)

Also Published As

Publication number Publication date
AR095235A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
MA42622B1 (en) LIAISONS IN TIGIT AND THEIR USES
MA46708B1 (en) Anti-pd1 antibodies and their uses
MA39313A1 (en) Anti-egfrviii antibodies and their uses in the treatment of various cancers
MA45125B1 (en) Anti-alpha-synuclein antibodies and their uses
MX2020012416A (en) Anti-il-33 antibodies and uses thereof.
MA46619B1 (en) Anti-il-33 antibodies and their uses
MA40609B1 (en) Cd123 binding agents and their uses
MA37945B1 (en) Human antibodies to gfr3 and methods of use thereof
MY165273A (en) Anti-cd48 antibodies and uses thereof
EA201890453A1 (en) ANTI-ANGPTL8 ANTIBODIES AND THEIR APPLICATION
DE602005021694D1 (en) COMBINATION THERAPIES AGAINST MULTIPLE FABRIC LIKE RECEPTORS AND THEIR USE
CA2868907C (en) Anti-hla-b*27 antibodies and uses thereof
MA33534B1 (en) Human antibodies have a high affinity against human 2 angiobots
MA38498B1 (en) Anti-lag-3 binding proteins
MA33402B1 (en) COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES
MA32566B1 (en) ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUSES AND USES THEREOF
MA40106A1 (en) Anti-il-25 antibodies and their uses
MA38478A1 (en) Human anti-pac1 antibodies
MA41072A1 (en) New pyoverine and pyochelin specific proteins
MX2018013072A (en) Tl1a antibodies and uses thereof.
MA38503A1 (en) Anti-il-33 antibodies and their uses
MA47976B1 (en) ANTIBODIES DIRECTED AGAINST TREM2 AND THEIR USE
MA38501B1 (en) Human antibodies to the respiratory syncytial virus protein f and its methods of use
MA38302B1 (en) Anti-pdgfr-beta antibodies and their uses
MA41666A1 (en) Anti-ox40 antibodies and their uses